PPARGC1A and malignant colon neoplasm: These findings are similar to the research of Vellinga et al. (14), who found that upregulating the PGC1α signaling pathway reduced the sensitivity to CDDP by transforming tumor metabolism from glycolysis to OXPHOS in colon cancer.